JLPC(SH:600513) Xin Lang Cai Jing·2025-10-31 23:18Core Insights - Lianhuan Pharmaceutical, established in 2000 and listed in 2003, focuses on the research, production, and sales of chemical pharmaceuticals, with a diverse product line and mature production processes [1] Financial Performance - For Q3 2025, Lianhuan Pharmaceutical reported revenue of 2.082 billion yuan, ranking 31st out of 110 in the industry, while the industry leader, East China Pharmaceutical, generated 32.664 billion yuan [2] - The company incurred a net loss of 27.7224 million yuan, ranking 79th in the industry, with the top performer, Heng Rui Pharmaceutical, achieving a net profit of 5.76 billion yuan [2] Financial Ratios - As of Q3 2025, Lianhuan Pharmaceutical's debt-to-asset ratio was 57.72%, up from 47.92% the previous year, exceeding the industry average of 35.26% [3] - The gross profit margin for Q3 2025 was 34.49%, down from 49.89% year-on-year, and below the industry average of 57.17% [3] Executive Compensation - The chairman, Qian Zhenhua, received a salary of 791,500 yuan in 2024, an increase of 31,200 yuan from 2023 [4] - The general manager, Niu Ben, earned 775,500 yuan in 2024, up by 65,700 yuan from the previous year [4] Shareholder Information - As of September 30, 2025, the number of A-share shareholders increased by 54.72% to 46,600 [5] - The average number of circulating A-shares held per shareholder decreased by 35.37% to 6,130.67 [5]